Indoco Remedies Ltd., a renowned player in the global pharmaceutical industry, has announced receiving tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets in 100 mg and 300 mg strengths. These tablets are the generic equivalent of the Reference Listed Drug, Invokana Tablets, […]
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), in adults with obesity but without type 2 diabetes. The study successfully met its primary endpoint, showing a statistically significant change in body weight from baseline. Effective Weight Reductions Observed […]
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP and GLP-1 hormone receptors. This medication is tailored for adults with obesity or overweight conditions associated with weight-related medical issues such as hypertension and type 2 diabetes. Zepbound is recommended […]
Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and Metformin hydrochloride, designed to improve glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive lifestyle intervention. ZITUVIMET: A New Adjunct in Diabetes Care With the […]
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada’s esteemed specialty pharmaceutical giant. This collaboration aims at the commercialization of Liraglutide, a sophisticated drug-device formulation. This game-changing combination has been curated for the proficient treatment and management of challenges like Type 2 diabetes and […]
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in obesity and related co-morbidities treatment. Alongside the acquisition, the two companies have announced a three-year research and development (R&D) collaboration to discover and develop new pharmaceutical solutions for obesity and […]
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]
TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin’s effectiveness as an adjunct to Metformin for treating adults with type 2 diabetes. The Phase 3 study, published in “Diabetes, Obesity and Metabolism,” highlights the positive impact of BRENZAVVY (bexagliflozin), 20 mg, in improving glycemic control and reducing systolic blood pressure levels. […]
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. Both studies successfully met all primary and key secondary objectives, showcasing the effectiveness of tirzepatide over a placebo. The results saw participants on tirzepatide, after […]
Eli Lilly and Company (Lilly) said that tirzepatide has shown superior efficacy over placebo in chronic weight management, according to the results from the phase 3 clinical trial SURMOUNT-2. Tested on patients with obesity or overweight and type 2 diabetes, the trial reported that tirzepatide, at doses of 10 mg and 15 mg, led to […]